New Data Show Treatment with Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy Resulted in Favorable Structural Remodeling, Improvements in Cardiac...
InflaRx to cover costs of GOHIBIC for patients who are treated in line with its Emergency Use Authorization (EUA) but...
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the European regulatory filing for ACARIZAX® (house dust mite...
BOSTON and LONDON, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a global gene therapy leader, today announced the company...
Webinar to be hosted on January 31, 2024 at 1:00 pm. ETCHATHAM, N.J., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Tonix...
Collaboration will support the initiation of a combination arm in the ongoing Phase 1/2a trial in patients with mCRPC Enrollment...
Pamrevlumab has now completed Stage 2 of the trial and topline data from this registration study in ~175 pamrevlumab treated...
NEW YORK, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing...
Interim Data Analysis Anticipated in Mid-2024Expects Full Enrollment by Q1 2025 MINNEAPOLIS, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics,...
Diana Hausman, M.D., Accomplished Oncologist and Drug Developer, Appointed Chief Medical Officer Kyle Rasbach, Ph.D., Pharm.D., Experienced Biotechnology Portfolio Manager,...
Figure 1 Atacicept 72-week Data From the Phase 2b ORIGIN Trial Are Consistent With a Profile of True Disease Modification...
TURKU, Finland and BOSTON, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage...
Press Release Nicox Provides Fourth Quarter 2023 Financial and Business Highlights NCX 470 Phase 3 Denali clinical trial 75% randomizedNet...
PRESS RELEASE BioSenic presents new Phase 3 data on JTA-004 to treat severe osteoarthritis pain at the 2024 OARSI World...
GOTHENBURG, SWEDEN / ACCESSWIRE / January 25, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)Fourth quarter 2023 (October 1 - December 31)...
NMQF Releases Report that 56% of People of Color Live in Carcinogenic Environments; Announce Public-Private Collaboration to Address ProblemWashington, D.C.--(Newsfile...
GOTHENBURG, SE / ACCESSWIRE / January 24, 2024 / XVIVO Perfusion AB (STO:XVIVO) (LSE:0RKL)(FRA:3XV) In a recently published clinical trial...
The follow-on funding is a draw down from the $10 million private placement agreement entered into September 25 2023.Use of...
* New clinical trials have confirmed that Thermobalancing therapy with Dr Allen's Device is the first natural treatment option for...
HAMILTON, BERMUDA, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Altamira’s polyKRASmut siRNA shown to knock down at least 65-91% of KRAS...